文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

宫颈癌IMPT与螺旋IMRT计划质量及稳健性评估

Evaluation of plan quality and robustness of IMPT and helical IMRT for cervical cancer.
PubMed 文献 · Radiat Oncol · 2020-02-13

该研究对18例宫颈癌患者分别生成点扫描稳健IMPT(SRO)与螺旋断层稳健IMRT(TRO)计划,比较名义计划质量与28种扰动场景下的稳健性。SRO在靶区与OAR剂量学评分、直肠和乙状结肠NTCP及靶区覆盖稳健性方面均优于TRO。

要点

  • SRO名义计划靶区评分16.5 vs TRO 15.1,OAR评分60.9 vs 53.3。
  • SRO直肠NTCP 2.8% vs TRO 4.8%,乙状结肠5.2% vs 5.7%(均p<0.05)。
  • SRO靶区覆盖DVHBW 0.6% vs TRO 2.1%,靶区稳健性更优。

核心结论

  • SRO名义计划获得更好的CTV覆盖和OAR保护,基于NTCP计算预期可小幅降低直肠毒性,且CTV靶区覆盖更稳健。

研究设计与样本

  • 对18例宫颈癌患者分别生成点扫描稳健IMPT(SRO)计划和螺旋断层稳健IMRT(TRO)计划。
  • 基于临床经验计算CTV和5个OAR的计划评分,基于LKB模型计算直肠和乙状结肠NTCP。
  • 在28种扰动场景下计算DVH带宽(DVHBW)以评估计划稳健性。

主要发现

  • SRO名义计划靶区指标平均评分高于TRO(16.5 vs 15.1),OAR指标平均评分亦高于TRO(60.9 vs 53.3)。
  • OAR评分优势涉及膀胱[V35,V45,Dmean,D2cc]、直肠[V40,V45,D2cc,Dmax]、肠管[V35,V40,V45,Dmax]、乙状结肠[V40,Dmax]和股骨头[V30,Dmax]。
  • NTCP计算显示SRO直肠毒性低于TRO(2.8% vs 4.8%,p<0.05),乙状结肠毒性亦较低(5.2% vs 5.7%,p<0.05)。
  • SRO靶区覆盖DVHBW小于TRO(0.6% vs 2.1%),表明SRO靶区计划更稳健。

关键数值与推荐

  • 靶区指标包括V46.8Gy、V50Gy、适形性和均匀性。
  • OAR指标包括膀胱V35、V45、Dmean、D2cc,直肠V40、V45、D2cc、Dmax,肠管V35、V40、V45、Dmax,乙状结肠V40、Dmax,股骨头V30、Dmax。
  • 稳健性评估采用28种扰动场景下的DVHBW。

临床怎么用

  • 宫颈癌放疗选择质子IMPT(SRO)相较于螺旋断层IMRT(TRO)可能改善靶区覆盖与OAR保护。
  • 基于NTCP模型,SRO预期可小幅降低直肠和乙状结肠毒性。
  • SRO在靶区覆盖上稳健性更优,扰动场景下剂量变化更小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both plan quality and robustness were investigated through comparing some dosimetric metrics between intensity modulated proton therapy (IMPT) and helical tomotherapy based intensity modulated radiotherapy (IMRT) for cervical cancer. METHODS: Both a spot-scanning robust (SRO) IMPT plan and a helical tomotherapy robust (TRO) IMRT plan were generated for each of 18 patients. In order to evaluate the quality of nominal plans without dose perturbations, planning scores (PS) on clinical target volume (CTV) and five organs at risk (OARs) based on clinical experience, and normal tissue complication probabilities (NTCP) of rectum and sigmoid were calculated based on Lyman-Kutcher-Burman (LKB) model. Dose volume histogram bands width (DVHBW) were calculated in 28 perturbed scenarios to evaluate plan robustness. RESULTS: Compared with TRO, the average scores of SRO nominal plans were higher in target metrics [V46.8Gy, V50Gy, Conformity and Homogeneity](16.5 vs. 15.1), and in OARs metrics (60.9 vs. 53.3), including bladder [V35,V45, Dmean,D2cc], rectum [V40,V45,D2cc,Dmax], bowel [V35,V40,V45, Dmax], sigmoid [V40,Dmax] and femoral heads [V30,Dmax]. Meanwhile, NTCP calculation showed that the toxicities of rectum and sigmoid in SRO were lower than those in TRO (rectum: 2.8% vs. 4.8%, p < 0.05; sigmoid: 5.2% vs. 5.7%, p < 0.05). DVHBW in target coverage for the SRO plan was smaller than that for the TRO plan (0.6% vs. 2.1%), which means that the SRO plan generated a more robust plan in target. CONCLUSION: Better CTV coverage and OAR Sparing were obtained in SRO nominal plan. Based on NTCP calculation, SRO was expected to allow a small reduction in rectal toxicity. Furthermore, SRO generated a more robust plan in CTV target coverage.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Shang H, Pu Y, Wang W, et al. Evaluation of plan quality and robustness of IMPT and helical IMRT for cervical cancer. Radiat Oncol. 2020. PMID: 32054496. doi:10.1186/s13014-020-1483-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。